Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer
News
Aduro Biotech is collaborating with Merck to study the combination of Aduro’s Listeria-based immunotherapy CRS-207 with Merck’s anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will ... Read more